The TWENTE clinical trial, which compared two second generation drug-eluting stents - zotarolimus and everolimus-eluting stents - established non-inferiority between the two stents as measured by the primary endpoint: target vessel failure (TVF) at one year. Both stents also demonstrated low rates of stent thrombosis. Trial results were presented at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation...
More...
More...